Study for pancreatic cancer using a biopsy-confirmed treatment approach
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer diagnosis must be confirmed by biopsy (a tissue sample)
- Your CT scan must match pancreatic cancer
- You must not have had chemotherapy before, or you must have had it at least 2 months ago for pancreatic cancer
- You should be able to do daily activities with limited help (ECOG performance status 0–2)
- You must be able to give informed consent and have a permanent address and phone number
- You must be age 18 or older and not be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses heat from a probe inserted through an endoscope to destroy pancreatic tumors that cannot be removed with surgery. It may help shrink or control the tumor and could be an option if other treatments have not worked.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a procedure that uses sound waves to heat and destroy part of the tumor, combined with an immunotherapy drug called pembrolizumab (Keytruda) that helps your immune system fight the cancer. It is for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
This study tests how safe and effective endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is for treating pancreatic growths that might become cancer or already are cancer. It is for people who are already scheduled to have this procedure as part of their care.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.